Marisa
Crespo Leiro

2024

1. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

   European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 5-17

2. Connective tissue amyloidosis in patients referred for orthopedic surgery. CONNECT-AMY study

   Medicina Clinica

3. Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain

   Nefrologia, Vol. 44, Núm. 5, pp. 709-720

4. Diagnosing transthyretin amyloidosis in patients with known genetic cardiomyopathies - opportunities and open questions. Response

   Revista Espanola de Cardiologia

5. Diagnosis of transthyretin amyloidosis in patients with established cardiomyopathy

   Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 347-349

6. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy

   European Journal of Heart Failure, Vol. 26, Núm. 3, pp. 612-615

7. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

   Transplant International , Vol. 37

8. Focused update 2023 delle linee guida ESC 2021 per la diagnosi e il trattamento dello scompenso cardiaco acuto e cronico

   Giornale italiano di cardiologia (2006), Vol. 25, Núm. 3, pp. 202-213

9. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

   European Journal of Heart Failure

10. Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis

    Medicina Clinica, Vol. 162, Núm. 7, pp. e1-e7

11. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 10, pp. 1529-1628.e54

12. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

    American Heart Journal, Vol. 267, pp. 52-61

13. Molecular states associated with dysfunction and graft loss in heart transplants

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 3, pp. 508-518

14. Predicting the development of heart failure in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 9, pp. 720-722

15. Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 304-313

16. Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure

    Revista Clinica Espanola, Vol. 224, Núm. 3, pp. 123-132

17. Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 634-644

18. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival

    American Journal of Transplantation, Vol. 24, Núm. 8, pp. 1414-1426

19. Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin

    Frontiers in Cardiovascular Medicine, Vol. 11

20. Repetitive ambulatory levosimendan as a bridge to heart transplantation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301